 |
Peptron’s Osong plant in North Chungcheong Province. (Photo: Peptron) |
[Alpha Biz= Paul Lee] Seoul, South Korea — Peptron announced that the completion date for its new manufacturing plant has been postponed from the end of 2026 to the first half of 2027, according to a regulatory filing on December 3.
The company disclosed that its investment for building a U.S. cGMP–grade dedicated sustained-release pharmaceutical manufacturing facility has increased from KRW 65 billion to KRW 89 billion. The investment period has also been extended from December 27, 2026 to June 30, 2027.
Peptron had initially expected to begin construction in March this year; however, the company has not yet received construction approval, leading to the delay. Once completed, the new facility is designed to provide Peptron with an annual production capacity of 10 million vials of sustained-release therapeutics.
A company representative stated, “The investment amount has changed due to the issuance of exchangeable bonds on July 28, and the investment period has been adjusted due to delays in securing construction approval.”
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
